MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Mutliple myeloma (MM) has one of the poorest prognosis of the hematological malignancies and novel therapeutic approaches are needed. Therapeutic induction of p53 might be important to evaluate the drugs either individually or in combination. Direct inhibition of MDM2 function by an MDM2 antagonist nutlin or blocking proteasomal degradation of p53 by a selective proteasome inhibitor velcade can stabilize p53 and activate the p53 apoptotic signaling pathway. We examined if inhibition of p53-MDM2 interaction by nutlin might potentiate the cytotoxic effects of velcade in MM cell lines and primary MM samples. Nutlin or velcade resulted in a reduction in cell proliferation or viability in MM cells harboring wild type p53. Nutlin plus velcade showed a synergistic anti-myeloma activity as evidenced by a significant increase of cytotoxicity with respect to each agonist alone. These effects were accompanied by accumulation of p53 and its two immediate downstream targets, p21 and MDM2, as well as caspase activation and induction of proapoptotic targets, PUMA, BAX and BAK. The induction of p53 target genes induced by nutlin and/or velcade was further validated by gene expression profiling and expression of some selective targets was quantified by qRT-PCR. These preclinical studies provide the framework for clinical trial of nutlin, alone and in combination with conventional and novel therapies such as velcade to increase efficacy and improve patient outcome in MM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632
Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53
Tao, W., & Levine, A. J. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.6.3077 · Cited by 355
Nutlin-3 protects kidney cells during cisplatin therapy by suppressing Bax/Bak activation
Jiang, M., Pabla, N., Murphy, R. F., Yang, T., Yin, X.-M., Degenhardt, K., White, E., & Dong, Z. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m606928200 · Cited by 97
Cited by
Targeting the MDM2-p53 protein–protein interaction for new cancer therapeutics
Wang, S., Zhao, Y., Bernard, D., Aguilar, A., & Kumar, S. (2012) · Topics in Medicinal Chemistry · doi:10.1007/978-3-642-28965-1_2 · Cited by 72
“Combination of Nutlin-3 with velcade, a proteasome inhibitor approved for the treatment of multiple myeloma, showed a synergistic activity in multiple myeloma cells harboring wild-type p53 [91].”
BackgroundKocik, J., Machula, M., Wisniewska, A., Surmiak, E., Holak, T. A., & Skalniak, L. (2019) · Cancers · doi:10.3390/cancers11071014 · Cited by 46
“Additionally, p53-induced repression of the anti-apoptotic protein, survivin was observed [96].”
Background
Metadata
- Authors
- Saha, M. N., Jiang, H., Jayakar, J., Reece, D., Branch, D. R., & Chang, H.
- Venue
- Cancer Biology & Therapy
- Publisher
- Informa UK Limited
- Published
- 2010-06
- Volume
- 9
- Issue
- 11
- Pages
- 936-944
- ISSN
- 1538-4047 (ISSN-L)
- 1555-8576
- OpenAlex
- W2060763507
- Cited by
- 82
- References
- 3
- FWCI
- 4.13
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.